T2 Biosystems, Inc.
101 Hartwell Avenue
Lexington, Massachusetts 02421
May 31, 2024
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Re: | T2 Biosystems, Inc. |
Registration Statement on Form S-3
Filed May 28, 2024
File No. 333-279740
To whom it may concern:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, T2 Biosystems, Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-279740) be accelerated by the Securities and Exchange Commission to 4:30 p.m. Washington D.C. time on June 4, 2024 or as soon as practicable thereafter.
The Company requests that we be notified of such effectiveness by a telephone call to N. Danny Shulman of Latham & Watkins LLP at (212) 906-4510 and that such effectiveness also be confirmed in writing.
| Very truly yours, | ||
| T2 Biosystems, Inc. | ||
| By: | /s/ John Sperzel | |
| John Sperzel | ||
| President, Chief Executive Officer and Chairman of the Board | ||
| cc: | Evan Smith, Latham & Watkins LLP |
Steven Stokdyk, Latham & Watkins LLP